Tropic, a British gene-editing startup, has raised $105 million in new financing to expand production of bananas that don’t brown https://t.co/zMZjWVHrPO ...

Advances in gene-editing are allowing fruits to be altered in new ways https://t.co/UlT1W5qJAO ...

Gene-editing is speeding up the development of new varieties of fruit https://t.co/1biv5z5bSg ...

Core Insights - Cellectis announced a decision from the Arbitral Tribunal regarding its arbitration with Servier related to the License Agreement established on March 6, 2019 [1][2] - The Tribunal partially terminated the License Agreement concerning product UCART19 V1 and mandated Cellectis to engage in discussions for a direct license at Allogene's request [2] Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing cell and gene therapies using its gene-editing platform [3] - The company specializes in allogeneic CAR T immunotherapies, aiming to provide off-the-shelf gene-edited CAR T-cells for cancer treatment [3] - Cellectis maintains in-house manufacturing capabilities, positioning itself as a comprehensive player in the gene editing value chain [3] Company Locations and Listings - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [4] - The company is publicly traded on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth under the ticker ALCLS [4]

Today on “The Intelligence”: was America’s deadly strike on a Caribbean ship a war crime, do US firms want to make gene-edited babies, and why women in Japan face a long fight to compete in sumo https://t.co/wkwnNKLej1 ...

Also on the daily podcast: Gene-editing babies in America and women’s sumo https://t.co/7KwnMM1vwS ...

New efforts to create gene-edited babies are taking off, promoted and funded by the billionaires of Silicon Valley https://t.co/ZKDfKzz6RR ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare diseases https://t.co/Q9MejyU7T0 ...

Company Overview - Nephrogen 是 Startup Battlefield 的亚军，是一家生物技术初创公司 [1] - 公司创建了一种基因编辑药物进入肾脏特定细胞的递送机制 [1] Technology & Innovation - 该递送机制的效率是当前方法的 100 倍 [1] Clinical Study - Nephrogen 的创始人将参与其临床研究 [1]

Core Viewpoint - CRISPR Therapeutics, despite a 24% decline in share price since mid-2022, has potential for significant returns due to its innovative gene-editing therapies, particularly with its first approved product, Casgevy [1][2]. Group 1: Product Development and Market Potential - CRISPR Therapeutics' first approved product, Casgevy, treats sickle cell disease and transfusion-dependent beta-thalassemia, marking a milestone as the first CRISPR-based gene-editing medicine approved [3]. - The treatment faces challenges, including a complex manufacturing process and a high cost of $2.2 million in the U.S., making reimbursement from third-party payers a significant hurdle [4]. - The company has activated 75 authorized treatment centers and secured reimbursement for eligible patients in 10 countries, targeting approximately 60,000 eligible patients [6]. Group 2: Financial Projections - If CRISPR Therapeutics can secure reimbursement for 70% of the target population and treat 30% over the next decade, Casgevy could generate over $27.7 billion, with CRISPR's share estimated at $11.1 billion [7]. - While Casgevy could contribute significantly to the company's revenue, it may primarily serve as proof of concept for the effectiveness of the biotech's approach [8]. Group 3: Future Pipeline and Growth Potential - CRISPR Therapeutics has six candidates in clinical trials, including CTX310, which shows promise in reducing LDL cholesterol and is easier to handle than ex vivo therapies [10]. - The company's future success relies on achieving consistent clinical and regulatory wins for CTX310 and other candidates, which could lead to a substantial increase in share price [11]. - A successful launch of new products in the next five to seven years could make gene-editing medicines more mainstream, encouraging third-party payers and healthcare institutions to support the treatments [12].